Full Press Release Details
LakeShore Biopharma Announces Transition to
OTC Market Following Nasdaq Delisting
BEIJING, September 22, 2025 /PRNewswire/ -- LakeShore
Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company
dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious
diseases and cancer, today announced that effective with the opening of business today, September 22, 2025, the Company's ordinary
shares and warrants have been suspended from trading on The Nasdaq Capital Market ("Nasdaq").
On the same day, the Company's ordinary
shares and warrants are expected to commence trading on the OTC Pink Open Market ("OTC Market") under the symbols "LSBCF"
and "LSBWF", respectively.
This action follows the receipt of a delisting
determination letter from Nasdaq on September 11, 2025, as previously disclosed by the Company on September 12, 2025. Nasdaq's determination
was based on the Company's non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and
its ineligibility for a compliance period under Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to a prior reverse stock split.
The transition to the OTC Market does not change
the Company's business operations. The Company remains a reporting company with the U.S. Securities and Exchange Commission and
is committed to maintaining transparency with its shareholders and the public.
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma,
is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines
and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology
platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections.
The Company operates in China, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and
global experience in the biopharmaceutical industry. For more information, please visit https://investors.lakeshorebio.com/.
Cautionary Statement Regarding Forward-Looking
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange
Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical
or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the Board's
evaluation of the Proposal Letter and the Proposed Transaction. Forward-looking statements may be identified by the use of words such
as "estimate," "plan," "project," "potential," "forecast," "intend,"
"will," "expect," "anticipate," "believe," "goal," "seek," "target"
or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These
statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma's
management and are not predictions of actual performance.
LakeShore Biopharma cannot assure you the forward-looking
statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties,
including those included under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the
Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the Company from time to time
with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes
are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the
significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by
any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the
date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may
update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable
law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date
subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update
these forward-looking statements.
Investor Relations Contact
Tel: +86 (10) 8920-2086
Email: ir@lakeshorebio.com